Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline vs Coasting for OHSS Prevention
NCT07043322Phase 2
Key facts
- Status
- Recruiting
- Start
- Jun 2025
- Primary completion
- Oct 2026
- Countries
- 1
- Sponsor
- Tanta University
- Modality
- Small Molecules
- Drugs
- cabergoline
- Conditions
- ovarian hyperstimulation syndrome (OHSS)
01
Overview
Phase 2, randomised trial of cabergoline in ovarian hyperstimulation syndrome (OHSS) (2 arms), sponsored by Tanta University. Primary endpoint: Occurrence and severity of Ovarian Hyperstimulation Syndrome at 1 month. Started Jun 2025; status: recruiting.
02
Design
2 arms- Study design
- Randomized
Control group
Coasting procedure only.
Cabergoline group
Coasting procedure plus Cabergoline 0.25 mg daily for 8 days.
03
Who it enrols
Women aged 18-38 with BMI < 30 undergoing a long luteal protocol for ovarian stimulation, who are at high risk of OHSS (>20 follicles >12 mm and/or E2 > 3000 pg/ml).
04
Endpoints
Primary
Occurrence and severity of Ovarian Hyperstimulation Syndrome
Beyond the preview
Go deeper on NCT07043322.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07043322.